---
title: "iVascular initiates Opal study with new embolic liquid"
date: "2024-11-11T13:50:08.000Z"
publishedDate: "11 novembre 2024"
summary: "iVascular has announced the initiation of Opal, the first-in-human study with the new embolic liquid Amber, based on a radiopaque biocompatible copolymer. Opal is a prospective, single-arm, multicentre study with a sample size of 70 patients requiring peripheral embolization."
importance: ""
sourceUrl: "https://interventionalnews.com/ivascular-initiates-opal-study-with-new-embolic-liquid/"
tags: ["France", "Actualité", "Interventional News — Latest"]
permalink: "/papers/2024-11-11-ivascular-initiates-opal-study-with-new-embolic-liquid"
imageUrl: "http://interventionalnews.com/wp-content/uploads/sites/13/2024/11/OPAL-AMBER.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://interventionalnews.com/ivascular-initiates-opal-study-with-new-embolic-liquid/"
---

![iVascular initiates Opal study with new embolic liquid](http://interventionalnews.com/wp-content/uploads/sites/13/2024/11/OPAL-AMBER.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://interventionalnews.com/ivascular-initiates-opal-study-with-new-embolic-liquid/*

## L’essentiel

iVascular has announced the initiation of Opal, the first-in-human study with the new embolic liquid Amber, based on a radiopaque biocompatible copolymer. Opal is a prospective, single-arm, multicentre study with a sample size of 70 patients requiring peripheral embolization.

## Lien source

https://interventionalnews.com/ivascular-initiates-opal-study-with-new-embolic-liquid/
